Abstract: Described herein is a stable oral liquid pharmaceutical product comprising sodium picosulfate, magnesium oxide and citric acid. Particularly, sodium picosulfate is physically separated from magnesium oxide and citric acid prior to dispensing and is mixed at the time of administration.

Abstract: The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents (darunavir, dolutegravir and ritonavir), the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of HIV infection.

Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.

Abstract: Described herein is a stable oral liquid pharmaceutical product comprising sodium picosulfate, magnesium oxide and citric acid. Particularly, sodium picosulfate is physically separated from magnesium oxide and citric acid prior to dispensing and is mixed at the time of administration.

Abstract: The present invention relates to pharmaceutical compositions of sacubitril; valsartan sodium and a process for the preparation thereof. Particularly, the present invention relates to stable non-aqueous based tablet composition of sacubitril; valsartan sodium and a process for the preparation thereof.

Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.

Abstract: The present invention relates to pharmaceutical compositions of enalapril, particularly stable oral liquid compositions comprising enalapril, one or more buffering agents and at least one pharmaceutically acceptable excipient.

Abstract: The invention relates to stable bilayer tablet compositions comprising empagliflozin, linagliptin and pharmaceutically acceptable excipients which show no incompatibilities and the compositions having good stability and superior dissolution profile.

Abstract: The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents (darunavir, dolutegravir and ritonavir), the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of HIV infection.

Abstract: The present invention relates to pharmaceutical antiretroviral compositions comprising a combination of antiretroviral agents, the manufacturing process thereof and use of the said compositions for the prevention, treatment or prophylaxis of diseases caused by retro viruses, specifically acquired immune deficiency syndrome or an HIV infection.

Abstract: The present invention is related to an anti-retroviral composition. In particular, the present invention relates to a solid oral composition comprising combination of multi-class drugs particularly darunavir, dolutegravir and cobicistat and process for preparing the same.

Abstract: The present invention relates to stable pharmaceutical compositions of sodium picosulfate, magnesium oxide and citric acid. The invention also relates to processes for the preparation of such compositions and its use for bowel cleansing.

Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.

Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and for water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The present invention provides stabilized prolonged release pharmaceutical compositions comprising atypical antipsychotic drug like paliperidone or pharmaceutically acceptable salts thereof without incorporating surfactant and/or water penetration enhancer. Such compositions are preferably in the form of a matrix wherein one or more release controlling agents are present in and/or on the matrix. Further, such compositions comprise one or more release controlling agent and exhibits desired in vitro release of drug with or without lag period. The invention also provides a process for the preparation of such compositions.

Abstract: The present invention provides extended release pharmaceutical compositions structured for once a day administration comprising skeletal muscle relaxant such as cyclobenzaprine or its pharmaceutically acceptable salt thereof that extends the release of the drug under in-vitro conditions for at least 8 to 12 hours. The invention also provides process for the preparation of such structured compositions.